3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Colorectal Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Sarcoma
1
Pyloric Stenosis, Hypertrophic
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphangioleiomyomatosis
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hematopoietic and Lymphatic System Neoplasm
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
Glioma
1
Early Detection of Cancer
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Bone Neoplasms
1
Interventions
Trastuzumab
8
pyrotinib
6
pertuzumab
4
Docetaxel
3
Capecitabine
3
tucatinib
2
Paclitaxel
2
Neoadjuvant Therapy
2
trastuzumab deruxtecan
1
neratinib
1
inavolisib
1
Taxoids
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Genetic Testing
1
Drug Therapy
1
Carboplatin
1
Blood Specimen Collection
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
HER2-positive Breast Cancer
×
Genetic Testing
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled